Arbeitspapier
Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts
- Language
-
Englisch
- Bibliographic citation
-
Series: Working Paper ; No. 217
- Classification
-
Wirtschaft
- Event
-
Geistige Schöpfung
- (who)
-
Philipson, Tomas J.
Berndt, Ernst R.
Gottschalk, Adrian H. B.
Sun, Eric
- Event
-
Veröffentlichung
- (who)
-
The University of Chicago, George J. Stigler Center for the Study of the Economy and the State
- (where)
-
Chicago, IL
- (when)
-
2007
- Handle
- Last update
-
10.03.2025, 11:44 AM CET
Data provider
This object is provided by:
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. If you have any questions about the object, please contact the data provider.
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. If you have any questions about the object, please contact the data provider.
Object type
- Arbeitspapier
Associated
- Philipson, Tomas J.
- Berndt, Ernst R.
- Gottschalk, Adrian H. B.
- Sun, Eric
- The University of Chicago, George J. Stigler Center for the Study of the Economy and the State
Time of origin
- 2007
Other Objects (12)
The FDA Changed Everything
A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
The FDA initiatives for personalized medicine
Cost-Benefit Analysis and the Democratic Ideal
Cost-benefit analysis of the community patent
FDA
FDA
FDA
FDA
The First FDA-Approved Antibody-Drug Conjugate
Additively manufactured medical products – the FDA perspective
The Mitigating Role of Prescription Drug Monitoring Programs in the Abuse of Prescription Drugs
The FDA Changed Everything
A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
The FDA initiatives for personalized medicine
Cost-Benefit Analysis and the Democratic Ideal
Cost-benefit analysis of the community patent
FDA
FDA
FDA
FDA
The First FDA-Approved Antibody-Drug Conjugate
Additively manufactured medical products – the FDA perspective
The Mitigating Role of Prescription Drug Monitoring Programs in the Abuse of Prescription Drugs
The FDA Changed Everything
A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
The FDA initiatives for personalized medicine
Cost-Benefit Analysis and the Democratic Ideal
Cost-benefit analysis of the community patent
FDA
FDA
FDA
FDA
The First FDA-Approved Antibody-Drug Conjugate
Additively manufactured medical products – the FDA perspective